> Detailanzeige

Martin, Matthew J.; Zain, Nur Masirah M.; Hearson, Glenn; Rivett, Damian W.; Koller, Garrit; Wooldridge, David J.; Rose, Graham; Gharbia, Saheer E.; Forbes, Ben; Bruce, Kenneth D.; Harrison, Tim W.

The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids
  • Beteiligte: Martin, Matthew J.; Zain, Nur Masirah M.; Hearson, Glenn; Rivett, Damian W.; Koller, Garrit; Wooldridge, David J.; Rose, Graham; Gharbia, Saheer E.; Forbes, Ben; Bruce, Kenneth D.; Harrison, Tim W.
  • Erschienen: Public Library of Science (PLoS), 2020
  • Erschienen in: PLOS ONE
  • Sprache: Englisch
  • DOI: 10.1371/journal.pone.0244681
  • ISSN: 1932-6203
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec id="sec001"><jats:title>Background</jats:title><jats:p>Inhaled corticosteroids (ICS) are the mainstay of asthma treatment, but evidence suggests a link between ICS usage and increased rates of respiratory infections. We assessed the composition of the asthmatic airways microbiome in asthma patients taking low and high dose ICS and the stability of the microbiome over a 2 week period.</jats:p></jats:sec><jats:sec id="sec002"><jats:title>Methods</jats:title><jats:p>We prospectively recruited 55 individuals with asthma. Of these, 22 were on low-dose ICS and 33 on high-dose ICS (16 on budesonide, 17 on fluticasone propionate). Sputum from each subject underwent DNA extraction, amplification and 16S rRNA gene sequencing of the bacterial component of the microbiome. 19 subjects returned for further sputum induction after 24 h and 2 weeks.</jats:p></jats:sec><jats:sec id="sec003"><jats:title>Results</jats:title><jats:p>A total of 5,615,037 sequencing reads revealed 167 bacterial taxa in the asthmatic airway samples, with the most abundant being<jats:italic>Streptococcus</jats:italic>spp. No significant differences in sputum bacterial load or overall community composition were seen between the low- and high-dose ICS groups. However,<jats:italic>Streptococcus</jats:italic>spp. showed significantly higher relative abundance in subjects taking low-dose ICS (p = 0.002).<jats:italic>Haemophilus parainfluenzae</jats:italic>was significantly more abundant in subjects on high-dose fluticasone propionate than those on high-dose budesonide (p = 0.047). There were no statistically significant changes in microbiota composition over a 2-week period.</jats:p></jats:sec><jats:sec id="sec004"><jats:title>Discussion</jats:title><jats:p>Whilst no significant differences were observed between the low- and high-dose ICS groups, increased abundance of the potential pathogen<jats:italic>H</jats:italic>.<jats:italic>parainfluenzae</jats:italic>was observed in patients taking high-dose fluticasone propionate compared to those taking high-dose budesonide. The microbiota were stable over fourteen days, providing novel evidence of the established community of bacteria in the asthmatic airways.</jats:p></jats:sec><jats:sec id="sec005"><jats:title>Clinical trial registration</jats:title><jats:p>ClinicalTrials.gov<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02671773" xlink:type="simple">NCT02671773</jats:ext-link></jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang